On Friday, Shares of Ralph Lauren Corp (NYSE:RL) subtract -2.16% and closed at $97.52 in the last trading session. The last trading range of the stock ranges between $97.50 and $100.88. Ralph Lauren Corporation designs, markets, and distributes lifestyle products worldwide. The company operates in three segments: Wholesale, Retail, and Licensing. It offers apparel, counting a range of men, women, and childrens clothing; accessories, which comprise footwear, eyewear, watches, fine jewelry, hats, belts, and leather goods, such as handbags and luggage; home products consisting of bedding and bath products, furniture, fabrics and wallpapers, lightings, paints, tabletops, and giftware; and fragrances. The company sells apparel and accessories under the Ralph Lauren Collection, Purple Label, Black Label, Polo Ralph Lauren, Polo Sport, Double RL, RLX Ralph Lauren, Lauren Ralph Lauren, Ralph by Ralph Lauren, Polo and RLX Golf, Ralph Lauren Children, Denim & Supply Ralph Lauren, Chaps, Club Monaco, American Living, and other brand names; women’s fragrances under the Safari, Ralph Lauren Blue, Lauren, Romance, RALPH collection, and Big Pony collection brand names; and men’s fragrances under the Safari, Polo Sport, Polo Green, Polo Blue, Polo Blue Sport, Purple Label, Polo Black, Double Black, Big Pony collection, Polo Red collection, and Polo Supreme Oud brand names. Ralph Lauren Corporation sells its products to department stores, specialty stores, and golf and pro shops, in addition to through its retail stores, concession-based shop-within-shops, and its e-commerce sites. The company also sells its apparel, home, and other products through licensing alliances.
Hormel Foods Corp (NYSE:HRL) dropped -0.34% and closed at $37.92 in the last trading session. The last trading range of the stock ranges between $37.87 and $38.16. The company’s Market capitalization is $20.00B with the total Outstanding Shares of $529.20M. Hormel Foods Corporation (HRL) recently declared a donation of more than 60,000 pounds of products to assist with Hurricane Matthew relief efforts in the U.S. and Haiti. The donation of shelf-stable products such as SKIPPY® peanut butter, SPAM® products, Hormel® Compleats® microwave meals and Hearty Creations™ products will be distributed by Convoy of Hope in the U.S., and Food For The Poor in Haiti.
“We hope our donations will assist those in need during this difficult time,” said Wendy A. Watkins, vice president of corporate communications at Hormel Foods. “All of those affected by Hurricane Matthew are in our thoughts and prayers.”
“We are thankful for the generous support of Hormel Foods,” said Hal Donaldson, president of Convoy of Hope. “They have facilitated us to give hope to working poor families at our community events, in addition to disaster survivors following the Louisiana floods and Hurricane Matthew.”
Biogen Inc (NASDAQ:BIIB) lost -1.33% and closed at $290.50 in the last trading session. The last trading range of the stock ranges between $290.13 and $297.34. New data from the clinical program for nusinersen, an investigational treatment for spinal muscular atrophy (SMA), were presented by Biogen (BIIB) and Ionis Pharmaceuticals (IONS) in the late-breaking session at the 2016 World Muscle Society Congress in Granada, Spain. The presentations included safety results from the interim analysis of the Phase 3 ENDEAR study in infantile-onset SMA (most likely to develop Type 1), encouraging preliminary results from NURTURE, a Phase 2 open-label study in pre-symptomatic infants, and a recent analysis of the ongoing Phase 2 open-label study in patients with later-onset SMA (consistent with Types 2 or 3).
“We continue to be encouraged by the consistently positive results with nusinersen across our clinical program, counting our first data in infants treated before they show signs of the disease,” said Wildon Farwell, senior director SMA clinical development at Biogen. “NURTURE is the first study to evaluate an investigational therapy in pre-symptomatic infants genetically at risk for SMA. In this analysis, infants treated for up to one year achieved motor milestones in timelines more consistent with normal development than what is observed in the natural history of patients with Type 1 SMA.”